Restricted accessEditorialFirst published online 2013-12
Rebuttal to the letter ‘Meta-analysis of biodegradable versus durable polymer drug eluting stents in coronary artery disease: The reality?' of Kwong et al.
LupiARognoniASeccoGG. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients. Eur J Prev Cardiol2012; in press.
2.
OstojicMSagicDBeleslinB. First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention2008; 3: 574–579.
3.
XuBDouKFHanYL. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. Chin Med J (Engl)2011; 124: 811–816.
4.
Higgins JPT and Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 Updated March 2011. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
5.
NavareseELupiABuffonA. Meta-analysis of non-randomized studies in interventional cardiology: A critical appraisal. Ital J Public Health2009; 6: 303–306.
6.
ByrneRAKufnerSTirochK. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart2009; 95: 1489–1494.
